Results 181 to 190 of about 999,131 (304)

Disseminated drug-resistant nocardiosis in a patient with advanced HIV. [PDF]

IDCases
Epling BP, Manion M, Laidlaw E, Abers MS, Sereti I.   +4 more
europepmc   +1 more source

Peroxidasin enables melanoma immune escape by inhibiting natural killer cell cytotoxicity

Molecular Oncology, EarlyView.
Peroxidasin (PXDN) is secreted by melanoma cells and binds the NK cell receptor NKG2D, thereby suppressing NK cell activation and cytotoxicity. PXDN depletion restores NKG2D signaling and enables effective NK cell–mediated melanoma killing. These findings identify PXDN as a previously unrecognized immune evasion factor and a potential target to improve
Hsu‐Min Sung, David Bickel, Lena C. M. Krause, Daria Ezeriņa, Christian Ickes, Julian Wojtachnia, Christine S. Gibhardt, Magdalena Shumanska, Khadija Wahni, Andrea Paluschkiwitz, Julia Malo Pueyo, Ekaterina Baranova, Wim Vranken, Hedwig Stanisz, Ioana Stejerean‐Todoran, Michael P. Schön, Joris Messens, Ivan Bogeski   +17 more
wiley   +1 more source

Editorial: Risk and protective factors in the natural history of autoimmunity. [PDF]

Front Immunol
Parks CG, Erdei EO, Miller FW.
europepmc   +1 more source

Phenotypic and genotypic characterization of single circulating tumor cells in the follow‐up of high‐grade serous ovarian cancer

Molecular Oncology, EarlyView.
Single circulating tumor cells (sCTCs) from high‐grade serous ovarian cancer patients were enriched, imaged, and genomically profiled using WGA and NGS at different time points during treatment. sCTCs revealed enrichment of alterations in Chromosomes 2, 7, and 12 as well as persistent or emerging oncogenic CNAs, supporting sCTC identity.
Carolin Salmon, Rui P. L. Neves, Nikolas H. Stoecklein, Sven‐Thorsten Liffers, Jens Siveke, Jan D. Kuhlmann, Pauline Wimberger, Paul Buderath, Rainer Kimmig, Sabine Kasimir‐Bauer   +9 more
wiley   +1 more source

Effects of the COVID-19 Pandemic on Tuberculosis Outcomes in the United States: A Bayesian Analysis. [PDF]

Clin Infect Dis
Swartwood NA, Cohen T, Marks SM, Hill AN, Beeler Asay GR, Self J, Feng PI, Horsburgh CR, Salomon JA, Menzies NA.   +9 more
europepmc   +1 more source

Combining antibody conjugates with cytotoxic and immune‐stimulating payloads maximizes anti‐cancer activity

Molecular Oncology, EarlyView.
Methods to improve antibody–drug conjugate (ADC) treatment durability in cancer therapy are needed. We utilized ADCs and immune‐stimulating antibody conjugates (ISACs), which are made from two non‐competitive antibodies, to enhance the entry of toxic payloads into cancer cells and deliver immunostimulatory agents into immune cells.
Tiexin Wang, Dong Jun Koo, Peter M. Tessier, Greg M. Thurber   +3 more
wiley   +1 more source

The Prostate is a Common Site of Disease in Patients with MEN2B and Medullary Thyroid Carcinoma. [PDF]

Endocr Relat Cancer
Kraft IL, Akshintala S, Gross A, Dombi E, Turkbey B, Bednarova S, Ward JF, Yedururi S, Merino M, Pinto PA, Widemann BC, Shern JF, Waguespack SG, Glod J.   +13 more
europepmc   +1 more source

Autografts in Psoriasis**From the Dermatology Branch, National Cancer Institute, National Institutes of Health, Bethesda, Maryland 20014. Public Health Service, U.S. Department of Health, Education, and Welfare.

Journal of Investigative Dermatology, 1965
Clendenning, William E., van Scott, Eugene J.   +1 more
openaire   +1 more source

Dammarenediol II enhances etoposide‐induced apoptosis by targeting O‐GlcNAc transferase and Akt/GSK3β/mTOR signaling in liver cancer

Molecular Oncology, EarlyView.
Etoposide induces DNA damage, activating p53‐dependent apoptosis via caspase‐3/7, which cleaves PARP1. Dammarenediol II enhances this apoptotic pathway by suppressing O‐GlcNAc transferase activity, further decreasing O‐GlcNAcylation. The reduction in O‐GlcNAc levels boosts p53‐driven apoptosis and influences the Akt/GSK3β/mTOR signaling pathway ...
Jaehoon Lee, Byung‐Cheol Han, Gi‐Bang Koo, Jihye Park, Mijin Kwon, Young Bin Park, Jae‐Mun Choi, Seung‐Ho Lee, Sangho Roh   +8 more
wiley   +1 more source

Pembrolizumab in recurrent or metastatic medullary thyroid cancer. [PDF]

Oncologist
Del Rivero J, Donahue RN, Marte JL, Gramza A, Cordes L, Karzai F, Abel ML, Schlom J, Gulley JL, Madan RA.   +9 more
europepmc   +1 more source